Titan America (NYSE:TTAM) reported second-quarter 2026 revenue growth and a modest increase in adjusted EBITDA, as strong Mid-Atlantic demand offset operational disruptions and softer residential construction conditions in Florida.
Revenue rose 9.6% year over year to $471 million, including a $20 m
Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a modest opening, just slightly higher than its initial pricing.
